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Epinephrine in cardiac arrest: systematic review and meta-analysis
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Objective: evaluate the effectiveness of epinephrine used during cardiac arrest and its effect on 
the survival rates and neurological condition. Method: systematic review of scientific literature 
with meta-analysis, using a random effects model. The following databases were used to research 
clinical trials and observational studies: Medline, Embase and Cochrane, from 2005 to 2015. 
Results: when the Return of Spontaneous Circulation (ROSC) with administration of epinephrine 
was compared with ROSC without administration, increased rates were found with administration 
(OR 2.02. 95% CI 1.49 to 2.75; I2 = 95%). Meta-analysis showed an increase in survival to 
discharge or 30 days after administration of epinephrine (OR 1.23; 95% IC 1.05-1.44; I2=83%). 
Stratification by shockable and non-shockable rhythms showed an increase in survival for 
non-shockable rhythm (OR 1.52; 95% IC 1.29-1.78; I2=42%). When compared with delayed 
administration, the administration of epinephrine within 10 minutes showed an increased survival 
rate (OR 2.03; 95% IC 1.77-2.32; I2=0%). Conclusion: administration of epinephrine appears to 
increase the rate of ROSC, but when compared with other therapies, no positive effect was found 
on survival rates of patients with favorable neurological status.
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Introduction
Cardiorespiratory arrest is the sudden and 
unexpected cessation of breathing and spontaneous 
circulation, that can be restored to a previous status, 
in those in whom a fatal outcome was not expected at 
that time(1). This is a major problem worldwide because 
the incidence is estimated at around 55 out-of-hospital 
cardiac arrests in adults per 100,000 people, of whom 
only 7% survive(2).
As regards in-hospital cardiac arrests, relevant 
findings in the literature were scarce,  but estimates 
indicate that the incidence could be between 1 and 5 
cases per 1.000 admissions per year, and the overall 
survival varies between 10% and 42%(3).
The treatment of cardiorespiratory arrest follows 
recommendations published every five years, based 
on a number of reviews by the International Liaison 
Committee on Resuscitation (ILCOR), an organization 
formed by leading global councils and Resuscitation 
associations. Outstanding among them are the American 
Heart Association (AHA) and European Resuscitation 
Council (ERC). Both AHA and ERC recommendations, 
from 2010 and 2015, have indicated that controlled 
clinical trials of vasopressors vs. placebo are needed. 
With the present evidence, the use of epinephrine 
in cardiac arrest is recommended as class IIb(4). This 
should be considered, as the benefits may outweigh the 
risks; therefore both organizations recommend the use 
of 1 mg of epinephrine every 3-5 min. However AHA has 
indicated that 40UI of vasopressin may replace the first 
or second dose of epinephrine(5-9). 
Epinephrine is one of three natural catecholamines, 
along with norepinephrine and dopamine, that has 
a potent stimulatory action on α and β receptors 
distributed throughout the body; in the heart increases 
the flow speed, the heart rate and the force of 
contraction (chronotropic and inotropic effects on the 
heart) therefore increases the volume per minute, 
the systolic blood pressure and simultaneously the 
myocardial oxygen consumption. High doses produce 
extrasystoles and cardiac arrhythmias; they (high 
doses) also produce a rise in blood pressure (especially 
diastolic) that facilitates venous return and ventricular 
filling during diastole by stimulating α and β receptors. 
This increases total peripheral resistance, thus causing 
an increase in differential tension and tachycardia. If 
hypertension is high it can cause reflex bradycardia. 
Excessive and prolonged activation of the myocardium is 
dangerous; this could cause improper increased oxygen 
consumption and micro injuries that may appear in the 
vessels and myofibrils(10).
Based on the foregoing discourse, the question 
arises about the effect of epinephrine on survival of 
patients suffering cardiac arrest and on the neurological 
status of survivors of these cardiac events. 
The objective of the review was to investigate the 
scientific production and evaluate the effectiveness of 
epinephrine in treatment of cardiac arrest in terms of 
survival and neurological status.
Method 
A systematic review of the scientific literature 
was performed, with meta-analysis of the results. The 
search was conducted in Medline, Embase and Cochrane 
databases, between 01/01/2005 and 02/28/2015, using 
free-text terms and MeSH terms: “Heart arrest”, “Out-
of-Hospital Cardiac Arrest”, “Death, Sudden, Cardiac”, 
“Ventricular Fibrillation”, “Pulseless Electrical Activity” 
plus the Boolean operator “AND” with the terms 
“epinephrine”, “adrenaline” (Figure 1). This search 
strategy was adapted to other databases. The full search 
strategy can be provided by the authors. 
#1 Heart arrest
#2 Out-of-Hospital cardiac arrest
#3 Death, Sudden, Cardiac
#4 Ventricular fibrillation
#5 Pulseless electrical activity
#6 Epinephrine
#7 Adrenaline
#8 (#1 OR #2 OR #3 OR #4 OR #5) AND (#6 OR #7)
Figure 1 - Search strategy
Inclusion criteria
Experimental and cohort studies, published 
between 01/01/2005 and 01/07/2016, evaluating 
the effectiveness of epinephrine in adults with 
cardiorespiratory arrest, compared with other therapies 
or without administration of a vasoactive drug.
Outcome measures
The main outcome measure was survival to 
discharge/30 days. Secondary outcome measures were: 
survival to discharge/30 days with favorable neurologic 
status, one year survival, and one year survival with 
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favorable neurologic status and return of spontaneous 
circulation. The neurological status was considered 
favorable when the patient presented score 1 or 2 on 
the  Glasgow-Pittsburg scale “Cerebral Performance 
Category”(CPC)(11-12).
Data collection instrument
The outcomes of the bibliographic search were 
collected in a standardized data collection record that 
contained the following items:: author, year, title, purpose, 
hypothesis, type of study, randomization, blind, country, 
study duration, number of centers studied, inclusion and 
exclusion criteria, population, place of cardiac arrest 
(out-of-hospital or in-hospital) resuscitation guidelines, 
outcome measures, interventions, patient demographics 
and main outcomes.
Descriptive and thematic analysis
The STROBE questionnaire was used to assess 
the quality of observational studies, and the CONSORT 
questionnaire to evaluate clinical trials(13-14).
Data on clinical outcomes were grouped into short 
term and long term - the most common forms in cardiac 
arrest studies. The outcome measures were defined 
as follows: 1) return of spontaneous circulation, as an 
outcome measure in the short term and 2) survival 
to discharge/30 days, as an outcome measure in the 
long term. In the latter, the patient survived ≥30 
days after cardiac arrest or left the hospital alive with 
favorable neurological function, obtaining a score in the 
categories of Glasgow-Pittsburgh brain performance of 
1 (good cerebral performance) or 2 (moderate cerebral 
disability).
Meta-analysis
Due to the heterogeneity of the effects contained 
in the studies included, data were analyzed using the 
Mantel-Haenszel random effects model, which was 
the model that best fitted for unifying the results and 
evaluating comparisons between epinephrine vs. no 
epinephrine. For other comparisons, the fixed effects 
model was used. A 95% interval of confidence (IC) 
was defined for both models. Statistical heterogeneity 
was assessed using the I2 statistic. The cut-off scores 
of I2 ≤25%, I2 26–50% and I2> 50% were used to 
define statistical heterogeneity as low, moderate, and 
significant, respectively (15). Publication bias was assessed 
by using funnel plots and Egger’s test. Analyses were 
performed using the Cochrane Review Manager software 
(RevMan, version 5.3.5)
Subgroup analysis
Interventions and outcome measures (when 
stratified data by initial heart rhythm were found) were 
stratified by initial rate of cardiac arrest: shockable 
rhythm (ventricular fibrillation and pulseless ventricular 
tachycardia) and non-shockable rhythm (pulseless 
electrical activity and asystole).
Results
Characteristics of studies included
After eliminating duplicate citations, 2239 
references were identified. Of these, 9 randomized 
clinical trials and 17 observational studies were included. 
Details of studies selected are shown in Figure 2. 
Figure 2 - Flow diagram of the study selection process. 
2015
These studies were classified categorically, based 
on intervention and comparator. A summary of the 
characteristics of the studies included is shown in 
Figure 3.
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Study Design Country Type of  CRA* Intervention Comparator Place of intervention Quality









Callaway, 2006(17) RCT|| USA CRA Out-of-hosp. Epinephrine+ vasopressin
Epinephrine 
+placebo Out-of-hosp. Consort 17/25







multiple times of 
administration
In-hosp. Strobe 20/22






Epinephrine Out-of-hosp. Consort 23/25
Dumas, 2014(20) Cohort France CRA Out-of-hosp. non-traumatic Epinephrine No epinephrine Out-of-hosp. Strobe 20/22
Goto, 2013(21) Cohort Japan CRA Out-of-hosp. Epinephrine No epinephrine Out-of-hosp. Strobe 20/22











+vasopressin Epinephrine Out-of-hosp. Consort 22/25
Hagihara, 2012(24) Cohort Japan CRA Out-of-hosp. not witnessed by ET¶ Epinephrine No epinephrine Out-of-hosp. Strobe 20/22
Hayashi, 2012(25) Cohort Japan
CRA Out-of-hosp. 




Epinephrine No epinephrine Out-of-hosp. Strobe 20/22
Jacobs, 2011(26) RCT Australia
CRA Out-of-hosp. 
with CPR** initiated 
by the ET
Epinephrine Placebo Out-of-hosp. Consort 21/25








Machida, 2012(28) Cohort Japan CRA Out-of-hosp. attended by the ET Epinephrine No epinephrine Out-of-hosp. Strobe19/22
Mally, 2007(29) Cohort Slovenia CRA Out-of-hosp. attended by the ET
Epinephrine 
+vasopressin Epinephrine Out-of-hosp. Strobe 18/22
Mentzelopoulos, 
2009((30) RCT Greece
















placebo In-hosp. Consort 24/25
Mukoyama, 
2009(32) RCT Japan
Adults with CRA 
Out-of-hosp. not 
witnessed by ET Vasopressin Epinephrine Out-of-hosp. Consort 17/25
Nakahara, 2012(33) Cohort Japan
CRA Out-of-hosp. 
witnessed with 









Nakahara, 2013(34) Cohort Japan CRA Out-of-hosp. not witnessed Epinephrine No epinephrine Out-of-hosp. Strobe 21/22
Neset, 2013(35) Cohort Sweden CRA Out-of-hosp. non-traumatic Epinephrine No epinephrine Out-of-hosp. Strobe  20/22
Nordseth, 2012(36) RCT Sweden
CRA Out-of-hosp. 
with initial arrest 
rhythm of PEA††




non-traumatic,  not 
witnessed by ET
Epinephrine No epinephrine Out-of-hosp. Strobe 20/22
(the Figure 3 continue in the next page...)
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Study Design Country Type of  CRA* Intervention Comparator Place of intervention Quality
Ong, 2007(38) Cohort Singapore CRA Out-of-hosp. Epinephrine No epinephrine Out-of-hosp. Strobe 20/22
Ong, 2012(39) RCT Singapore CRA Out-of-hosp. Epinephrine+ vasopressin Epinephrine Out-of-hosp. Consort 23/25
Warren, 2014(40) Cohort USA CRA during hospitalization Epinephrine
Comparison 





CRA Out-of-hosp.,  
transfer to hospital . Epinephrine No epinephrine Out-of-hosp. Strobe 19/22
*CRA: cardiorespiratory arrest; †Out-of-hosp.: out-of-hospital; ‡In-hosp.: in-hospital; §mg: milligram; ||RCT: Randomized Clinical Trial; ¶ET: emergency 
team; ** CPR: cardiopulmonary resuscitation; †† PEA: pulseless electrical activity
Figure 3 - Characteristics of included studies, 2015
Epinephrine vs. no epinephrine 
Ten observational studies and two clinical trials 
(n=655.192 patients in 12 studies) compared the 
administration of epinephrine with no administration 
of epinephrine or with placebo(20-21,24-26,28,34-38,41). Meta-
analyses showed an increase in survival to hospital 
discharge/30 days related to administration of 
epinephrine(OR 1.23; 95% IC 1.05-1.44; I2=83%). 
Stratified by ventricular fibrillation (VF) / ventricular 
tachycardia (VT) and pulseless electrical activity (PEA), 
the table shows an increase in survival to PEA/asystole 
(OR 1.52; 95% IC 1.29-1.78; I2=42%), but no significant 
differences were observed in VF / VT (OR 1.10; 95% IC 
0.89-1.36; I2=63%) (Figure 4).
Figure 4 - Survival to discharge/30 days. Epinephrine vs. No epinephrine stratified by FV/TV and PEA/Asystole
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In the outcome survival to discharge/30 days with 
favorable neurologic status no significant differences 
were observed (OR 0.64; 95% IC 0.42-1.02; I2=96%). 
Nor were any significant stratified differences found by 
VF / VT (OR 0.66; 95% IC 0.29-1.51; I2= 98%) and 
PEA/asystole (OR 0.77; 95% IC 0.50-1.18; I2=75%).
Only one observational study(37) related to 1-year 
survival, was found, in which survival decreased with 
administration of epinephrine (OR 0.46; 95% IC 0.27-
0.78).
Increased return of spontaneous circulation was 
observed with administration of epinephrine (OR 2.02; 
95% IC 1.49-2.75; I2=95%). When stratified by VF/VT 
no significant differences were found (OR 1.26; 95% 
IC 0.90-1.76; I2=94%), whereas PEA/asystole showed 
an increase in return of spontaneous circulation with 
administration of epinephrine (OR 2.10; 95% IC 1.17-
3.77; I2=99%).
Epinephrine vs. Epinephrine + Vasopressin
Four randomized clinical trials and two observational 
studies (17,19,22-23,29,39) (n=4.358 patients included in these 
studies) compared the administration of epinephrine 
with the combination of epinephrine and vasopressin. 
The meta-analysis showed no significant differences in 
survival to hospital discharge/30 days (OR 0.94; 95% IC 
0.70-1.26; I2=12%).
No significant differences were observed at hospital 
discharge/30 days with favorable neurologic status (OR 
0.83; 95% IC 0.55-1.26; I2= 71%).
No significant differences were found in 1-year 
survival (OR 1.40; 95% IC 0.85-2.31; I2= 31%).
For 1-year survival with favorable neurologic status, 
only one observational study showed this outcome(39), 
in which no significant differences were observed (OR 
1.06; 95% IC 0.31-3.63).
In the return of spontaneous circulation, no 
significant differences were observed (OR 0.95; 95% 
IC 0.84-1.08; I2= 39%). Stratified by VF/VT (OR 0.94; 
95% IC 0.76-1.17; I2=0%) and PEA/asystole (OR 0.96; 
95% IC 0.58-1.56; I2=0%) no significant differences 
were observed.
Epinephrine + placebo vs. Epinephrine + vasopressin 
+ methylprednisolone
Two randomized clinical trials compared 
administration of epinephrine alone with a 
combination of epinephrine plus vasopressin and 
methylprednisolone(30-31). The meta-analysis showed 
an increase in return of spontaneous circulation 
when epinephrine combined with vasopressin and 
methylprednisolone was administered (RR 1.34; 95% IC 
1.18-1.52; I2= 37%).
Epinephrine vs. Vasopressin
In 2 randomized clinical trials(38-39) that compared 
the administration of epinephrine combined with 
vasopressin, no significant difference was found in 
survival to hospital discharge/30 days (RR 1.48; 95% 
IC 0.55-3.98); same outcome was found for return of 
spontaneous circulation (RR 1.08; 95% IC 0.76-1.53).
Epinephrine vs. Epinephrine + vasopressin + 
nitroglycerin
A randomized clinical trial compared the 
administration of epinephrine with epinephrine combined 
with vasopressin and nitroglycerin. In this study there 
was no significant difference between the combination 
and epinephrine alone(19).
Early administration of epinephrine vs. late 
administration of epinephrine
Two observational studies (n=49.851 patients 
included in these studies) compared early administration 
of epinephrine (before 10 minutes) with late 
administration (after 10 minutes)(27,33). 
The meta-analysis showed an increase in survival 
to hospital discharge/30 days for early administration 
(before 10 minutes) when compared with late 
administration (OR 2.03; 95% IC 1.77-2.32; I2=0%). 
An observational study(18) showed a decrease in survival 
to hospital discharge/30 days, when epinephrine was 
administered in more than 9 minutes (OR 0.63; 95% IC 
0.52-0.76).
Dose of epinephrine administered
An observational study that compared different 
doses of epinephrine(16) showed that  administration in 
high doses (greater than 5.5 mg) increased hospital 
mortality (OR 2.82; 95% IC 1.64-4.85); and increased 
rates of hospital mortality and unfavorable neurological 
status (OR 2.95; 95% IC 1.67-5.22).
Time between doses of epinephrine
An observational study that compared the time 
between doses of epinephrine during cardiac arrest(40) 
observed that when doses far apart (more than 5 
minutes) were compared with administration every 1-5 
minutes, the former decreases the survival rate (OR 
2.17; 95% IC 1.62-2.92).
The summary of results is shown in Table 1.
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Table 1 -  Summary of results. Spain, 2015
Outcome measures Interventions Outcomes
Outcomes stratified
VF/VT* PEA†/Asystole
Survival to hospital 
discharge/30 days
Epinephrine vs.‡ no epinephrine OR§ 1.23(1.05-1.44) OR 1.10 (0.89-1.36) OR 1.52 (1.29-1.78)
Epinephrine+ Vasopressin vs. 
Epinephrine OR 0.94 (0.70-1.26)
Vasopressin vs. Epinephrine RR|| 1.48 (0.55-3.98) 
Administration <10 min¶ vs. 
Administration >10 min OR 2.03 (1.77-2.32)
Survival to hospital 
discharge/30 days with 
favorable neurologic 
status (CPC** 1-2)
Epinephrine vs. no epinephrine OR 0.64 (0.42-1.02) OR 0.66 (0.29-1.51) OR 0.77 (0.50-1.18)
Epinephrine+ Vasopressin vs. 
Epinephrine OR 0.83 (0.55-1.26
1-year survival
Epinephrine vs. no epinephrine OR 0.46 (0.27-0.78) 
Epinephrine + Vasopressin  vs. 
Epinephrine OR 1.40 (0.85-2.31)
1-year survival with 
favorable neurologic 
status (CPC 1-2)
Epinephrine + Vasopressin  vs. 
Epinephrine OR 1.06 (0.31-3.63) 
Return of spontaneous 
circulation
Epinephrine  vs. no epinephrine OR 2.02 (1.49-2.75) OR 1.26 (0.90-1.76) p<0.001 OR 2.10 (1.17-3.77)
Epinephrine +Vasopressin  vs. 
Epinephrine OR 0.95 (0.84-1.08) 
OR 0.94 (0.76-
1.17) OR 0.96 (0.58-1.56)
Vasopressin  vs. Epinephrine RR 1.08 (0.76-1.53) 
Epinephrine +vasopressin 
+methylprednisolone  vs. Epinephrine 
+placebo
RR 1.34 (1.18-1.52) 
*VF/VT: Ventricular Fibrillation/Ventricular Tachycardia; †PEA: Pulseless Electrical Activity; ‡OR: Odds Ratio; §vs.: versus; ||RR:  Relative Risk ; ¶min.: 
minute; **CPC: Cerebral Performance Category
Discussion
In this systematic review and meta-analysis, a 
comparison was evaluated of epinephrine effectiveness 
during cardiac arrest with the use of other therapeutic 
options. 
 We did not find other comprehensive reviews and 
meta-analysis evaluating doses of epinephrine, time 
between doses, cumulative doses and short-term and 
long-term effects, especially in terms of neurological 
status. Instead we found systematic reviews and 
meta-analysis, in which the effect of epinephrine was 
compared with the use of other therapies for cardiac 
arrest. 
Regarding the survival to hospital discharge/30 days 
when epinephrine was administered in comparison with 
no administration of the drug, we found contradictory 
outcomes. The administration of epinephrine improved 
the rate of survival to hospital discharge/30 days(37). 
However, another research(21) stated otherwise; however, 
when the results were stratified by initial non-shockable 
rhythm the two findings coincided. 
Ong et al.(38) stated that there were no clear benefits 
administering epinephrine or not, thus this author was in 
agreement with Dumas et al.(20), who supported better 
outcomes when epinephrine was not administered. In 
their randomized clinical trial(39) the combination of 
epinephrine and vasopressin did not increase the long-
term survival rates, but they noted an increase in the 
number of patients arriving at the hospital admission 
with spontaneous circulation. On the contrary(23), they 
established favorable results for the group of patients 
who received epinephrine as a single therapy, but 
the difference in comparison with the combination of 
epinephrine and vasopressin, was not significant.
Our findings suggested that epinephrine increased 
the achievement of the return of spontaneous circulation, 
especially when epinephrine was administered in 
a short period of time. This result was corroborated 
by other systematic reviews and meta-analysis that 
support the benefit of epinephrine in terms of short-
term survival(42-48).
As regards the neurological status, we found 
no significant differences, but the results seemed 
www.eerp.usp.br/rlae
8 Rev. Latino-Am. Enfermagem 2016;24:e2821
to show a decrease in rates of favorable neurological 
status when epinephrine was used, especially when 
doses were higher; However an increase in rates of 
favorable neurological status was found when combined 
vasopressin and epinephrine were administered, which 
was in disagreement with the systematic review with 
meta-analysis(45). The authors stated that the increase 
in rates of favorable neurological status were higher in 
patients receiving standard doses of epinephrine.
We assumed that this decline in survival rates 
might be due to variations in heart rhythm induced by 
epinephrine in patients with reversed cardiac arrest, 
since this drug caused more instability in heart rhythm 
and complicated the patient’s treatment(35-36).
We could also assume that epinephrine tended to 
decrease the long-term survival rates, since it caused 
cardiac damage and increased consumption of oxygen 
in myocardial tissue.
Researchers found that patients treated with 
epinephrine for cardiac arrest and died, suffered 
subendocardial hemorrhage; this aspect was observed 
in forensic studies.
Our systematic review and meta-analysis had 
limitations. Firstly, most of the articles included were 
observational studies; therefore these uncontrolled 
studies included more bias in the results of the review. 
The second limitation was the lack of sufficient data 
related to some of the desired results, meaning that 
it was not possible to obtain statistically significant 
outcomes. The third limitation was the organizational 
structure of the emergency team and the training 
of its components in different countries, which 
introduced a bias that was not found in the articles 
researched.
On the other hand, most of the studies, included in 
this systematic review and meta-analysis, were published 
in high impact journals, located in the first quartile, such 
as: Resuscitation, The New England Journal of Medicine 
and The Journal of Emergency Medicine, among others.
Despite these limitations, the findings suggested 
that epinephrine had a positive effect on the early 
stages of cardiac arrest care, and favored the 
return of spontaneous circulation; however, it had a 
negative effect on survival in the short- and medium-
term and on the neurological status of the patient. 
This suggested that the current recommendations 
should be reviewed, limiting the number of doses 
of epinephrine administered in cardiac arrest; 
moreover, epinephrine must be indicated in cases of 
cardiac arrests with a concrete cause, avoiding its 
administration in cardiac arrest induced by coronary 
syndromes, for example.
Conclusion
The scientific evidence on the use of epinephrine 
in cardiorespiratory arrest was contradictory. We found 
epinephrine administration to be beneficial for the 
return of spontaneous circulation during resuscitation 
maneuvers; however, we did not find this benefit in the 
survival rate up to the time of discharge from hospital, in 
the long-term and on the neurological status of patients. 
We believe it is necessary to conduct high-
quality studies that take into account confounding 
variables, such as the quality of resuscitation, route of 
administration and numbers of doses, with the purpose 
of confirming the findings based on sufficient evidence.
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